Nanoparticles designed as messenger RNA (mRNA) carriers to deliver gene medicine have
shown great potential to change the way lung disease states are managed. Controlling their …

Messenger RNA (mRNA)–based therapeutics are transforming the landscapes of medicine,
yet targeted delivery of mRNA to specific cell types while minimizing off-target accumulation …

Antigen-specific particles can treat autoimmunity, and pulmonary delivery may provide for
easier delivery than intravenous or subcutaneous routes. The lung is a “hub” for …

Lipid nanoparticles (LNPs) carrying therapeutic mRNAs hold great promise in treating lung-
associated diseases like viral infections, tumors, and genetic disorders. However, because …

The lung remains an attractive target for the gene therapy of monogenetic diseases such as
cystic fibrosis (CF). Despite over 27 clinical trials, there are still very few gene therapy …

Inhalable messenger RNA (mRNA) has demonstrated great potential in therapy and vaccine
development to confront various lung diseases. However, few gene vectors could overcome …

mRNA therapeutics hold great potential for treating a variety of diseases through protein-
replacement, immunomodulation, and gene editing. However, much like siRNA therapy the …

An inhalable platform for messenger RNA (mRNA) therapeutics would enable minimally
invasive and lung-targeted delivery for a host of pulmonary diseases. Development of lung …

Achieving stable, efficient and non-toxic pulmonary gene delivery is most challenging
requirement for successful gene therapy to lung. Composite nanoparticles (NPs) of the poly …

Despite lipid nanoparticles'(LNPs) success in the effective and safe delivery of mRNA
vaccines, an inhalation-based mRNA therapy for lung diseases remains challenging. LNPs …